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Abstract 
Recombinant DNA technology has led to accelerating introduction of novel therapeutics 
for the treatment of hemophilia.  This technology has driven the development of recombinant 
clotting factors, extended half-life clotting factors, alternative biologics to promote hemostasis 
and enabled the launch of the gene therapy era for hemophilia.  At the core of this technology 
is the ability to study the structure and function of the native molecules and to apply rational 
bioengineering to overcome limitations to the existing therapies.  Through the study of 
hemophilia-causing mutations, site-directed mutagenesis, detailed structural models and a 
wide repertoire of animal models, new bioengineering strategies are helping overcome some of 
the remaining limitations and challenges of traditional clotting factor concentrates.  Some of 
these bioengineering strategies are now being partnered with improvements in vectorology 
leading to the first wave of successful gene therapy approaches.  This paper will review past 
and present bioengineered molecules that are advancing care for hemophilia as well as novel 
approaches that promise to continue to improve care and outcomes for patients with 
hemophilia.   
 
 
Introduction 
The initial wave of recombinant clotting factors provided a recombinant facsimile of 
their plasma-derived counterparts with remarkably similar biochemical, pharmacokinetic and 
pharmacodynamics properties[1].  Recombinant clotting factors have consistent manufacturing 
and processing liberated from the uncertainties of securing source plasma with at least the 
potential for an unlimited supply.  With increased supply, there has been an increase in the 
availability of clotting factors and increased utilization of prophylaxis in developed and 
developing countries[2, 3].  In many health systems, this has driven down the unit costs of 
replacement therapy and allowed for more aggressive prophylaxis regimens targeting higher 
trough levels and lower annualized bleed rates[4].  Extensive global safety reviews over the past 
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25 years have demonstrated no infectious pathogen transmission, no safety signals from 
adverse event reporting and no evidence of increased rate of inhibitors in previously-treated 
patients (PTPs)[5, 6].   
The remaining challenges in the recombinant era include barriers to the adoption and 
adherence to prophylaxis.  This can be attributed to the burden of a requirement for consistent 
venous access, time and costs of primary prophylaxis initiated in infants and young children and 
continued throughout adulthood[7].  In addition, recombinant factor VIII (rFVIII) products have 
not been shown to reduce the risk of inhibitor development among previously untreated 
patients (PUPs)[8].  This “natural” immune response to exposure to a foreign protein has been 
observed for all plasma-derived (pdFVIII) and rFVIII products with some studies demonstrating a 
significantly increased rate for the rFVIII[9].  There is considerable variability among patients 
with respect to phenotypic and pharmacokinetic variability.  Even among those who have 
benefitted from early introduction of continuous prophylaxis, annualized bleed rates are not 
zero for all patients with joint disease still appearing in young adults followed over 25-30 
years[10].  Further improvements in outcome can be achieved if patients have better bleed 
control.  This can occur through improved adherence, which can be facilitated through 
strategies that reduce the burden of administration – reduced dosing frequency, increased 
availability at reduced cost and application of alternative modes of delivery (eg. subcutaneous 
routes).  The challenge of inhibitors can be overcome with molecules with reduced or even 
absent immunogenicity or through highly efficacious bypassing activity[11].  
Basic research has provided insights on structure and function characterizations 
throughout the life cycles of FVIII and FIX including biosynthesis, macromolecular interactions, 
activation/inactivation, and clearance. Through the study of hemophilia-causing mutations, 
site-directed mutagenesis, detailed structural models and a wide repertoire of animal models, 
new bioengineering strategies are helping overcome some of the remaining limitations and 
challenges of traditional clotting factor concentrates[12].  Bioengineering strategies of biologics 
that can be applied to FVIII and FIX are summarized in Table 1.   Partnering these 
bioengineering strategies with improved viral vectors has produced the first wave of successful 
gene therapy approaches[13].  This paper will review past and present bioengineered 
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molecules that are advancing care for hemophilia as well as novel approaches that promise to 
continue to improve care and outcomes for patients with hemophilia. 
 
[Table 1] 
 
Bioengineering of FVIII 
Expression of rFVIII and its stability in plasma is limited by several mechanisms as 
summarized in Table 2.  One of the first innovations was removal of the FVIII B domain, 
accounting for ~38% of the primary cDNA sequence, without impairing important FVIII 
functions such as its affinity for von Willebrand factor (VWF) or its procoagulant activity[14, 15].  
This improved the yield of rFVIII in cell culture expression systems as a result of significantly 
increased mRNA and increased translation.  This was eventually characterized in clinical studies 
and demonstrated that clinical efficacy and rates of inhibitor formation in PUPs with hemophilia 
A were similar to that observed with full-length rFVIII products[16].  This molecule has since 
become the backbone for many additional biochemical modifications to extend its half-life 
including Fc-fusion and PEGylation, currently in clinical use.  However, its properties have been 
best exploited to advance gene therapy efforts.  The smaller size of the B domain-deleted FVIII 
(BDD-FVIII) cDNA helps facilitate more efficient packaging into viral vectors, such as adeno-
associated virus, which otherwise could not accommodate a full-length FVIII cDNA[13].  With 
similar biochemical characteristics to full-length FVIII, BDD-FVIII has now been incorporated into 
all active gene therapy programs for hemophilia A. 
B domain-deleted FVIII – the first bioengineered FVIII 
 
The genetic code, a triplet of bases of nucleotides, or codon, encoding for one amino 
acid, is degenerate.  As such, with the exception of two amino acids, Met and Trp, each amino 
acid can be encoded by one of several nucleotide triplet combinations, so-called synonymous 
codons[17, 18].  Codon usage bias varies between organisms related in part to organism-
specific differences in populations of cognate tRNAs[18].  Thus, frequently used codons will be 
Codon Optimization 
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translated more rapidly than infrequently used codons.  Codon optimization involves replacing 
rare codons with frequently used ones in order to increase the efficiency of protein expression.  
This has been used in one currently approved EHL rFIX (rFIX-FP)[19] and has become a mainstay 
of FVIII and FIX expression constructs used in gene therapy.  Codon optimization applied to 
BDD-FVIII can substantially increase the expression[20].  The improvement in FVIII expression 
efficiency can allow lower doses of viral vector and facilitate achieving higher levels of plasma 
expression.  However, a number of studies have demonstrated that synonymous codon 
changes can have unanticipated effects on protein conformation and stability, altered post-
translational modifications and protein function[21]. 
Codon usage is thought to determine the elongation rhythm, causing ribosomes to slow 
down or pause at certain sites, thereby modulating sequential folding events that occur co-
translationally[18, 21].  This differential synonymous coding is a secondary code guiding in vivo
 Codon optimization strategies are not standardized, and it is unlikely that any two 
codon-optimized FVIII or FIX constructs would be identical in sequence.  Given the potential 
adverse impact of the various synonymous mutations it is therefore critical to characterize fully 
the biochemical profile of the expressed protein as well as consider the potential for cellular 
stress effects through the impact of intracellular misfolded protein.  Shestopal et al. performed 
extensive biochemical characterization of a codon-optimized BDD-FVIII expressed in Chinese 
 
protein folding, thus it should not be surprising that studies have identified examples of 
synonymous codon changes affecting protein activity, interactions with drugs and inhibitors, 
phosphorylation profiles, sensitivity to limited proteolysis, spectroscopic properties, propensity 
for aggregation and protein structure (reviewed in [18]).  Notably, a naturally occurring 
synonymous codon change within the factor IX gene, c.459G>A (Val107Val), has been shown to 
be responsible for a case of hemophilia B[22] by significantly slowing FIX translation and 
affecting its conformation.  Codon optimization can also disrupt alternative start sites for 
translation, generating new sites that would encode novel peptides that could trigger immune 
reactions or interfere with normal cellular functions[21].  An alternative to codon optimization 
is codon harmonization, seeking to identify and maintain regions of slow translation thought to 
be important for protein folding[21, 23]. 
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hamster ovary cell lines[20].  Notably, the codon usage bias of Chinese hamsters is not very 
different from humans[17].  They observed that the codon-optimized BDD-FVIII was expressed 
7-fold higher, similar to prior experience with another codon-optimized BDD-FVIII[24], without 
evidence for a significant effect on its structure and function properties.  There were some 
differences observed for post-translational modifications including N- and O-glycosylation at 
specific sites and degree of Tyr-1680 sulfation.  They also noted an average specific activity that 
was 1.5-fold higher than wild-type FVIII and higher ratios of activities as measured by clotting 
assay or thrombin generation compared to chromogenic assay.  They attributed this to the 
quality of the preparations due to the higher protein concentrations and a higher abundance of 
single-chain BDD-FVIII.  However, this is an interesting observation given results from a recent 
hemophilia A gene therapy study.  A phase 1/2 study of BMN270, an AAV5 gene transfer of a 
BDD-FVIII in severe hemophilia A, produced sustained mean and median FVIII levels of 93% and 
77% respectively over a 1 year observation period.  Subjects demonstrated a consistent 
correlation of one-stage/chromogenic FVIII activity of 1.65, which would not have been 
expected based on observations with BDD-rFVIII produced recombinantly in cell lines[25].  
Future strategies for codon optimization will be driven by bioinformatics insights that are 
improving prior databases of codon usage tables[17] and through insights on the potential 
impacts of rare codon clusters on secondary protein structure. 
[Table 2] 
Expression of FVIII in heterologous mammalian cells is about 2 to 3 orders of magnitude lower 
than similarly sized proteins[26].  This inefficiency in expression contributes to low yields of 
recombinant protein production and must also be overcome in order to achieve efficacious 
plasma levels with hemophilia A gene therapy.  Some of the factors that contribute to this 
inefficiency are summarized in Table 2 and include: inefficient expression of the mRNA coupled 
with misfolding and degradation of a sizeable portion of the primary translation product[26, 
27]; retention of FVIII within the endoplasmic reticulum (ER) through interaction with several 
ER chaperones; formation of multiple disulfide bonds[28]; requirement for a facilitated 
transport mechanism comprising the mannose-binding lectin LMAN1 and MCFD2 for efficient 
Rational bioengineering through targeted mutagenesis 
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transport of FVIII from the ER to the Golgi[29, 30]; limited proteolysis within the Golgi, wherein 
a predominant cleavage occurs at the paired amino acid cleaving enzyme (PACE, or furin) 
recognition motif at the carboxy-terminus of the B domain yielding a heterodimer FVIII 
polypeptide consisting of heavy and light chains associated through a metal ion-dependent 
association;  the predominant heterodimeric form that is secreted requires stabilization by von 
Willebrand factor (VWF)[31].  
 Over the past decade, insights from this analysis of FVIII structure and function has 
delineated rational bioengineering strategies to overcome many of the limitations of FVIII 
expression (summarized in Table 2).  Since these bioengineering efforts have targeted different 
aspects of FVIII biosynthesis, folding, chaperone interactions, proteolytic processing, secretion 
and stabilization, combining these targeted modifications can have an additive effect with 
bioengineered variants exhibiting up to 50-fold improvement over wild-type FVIII expression.  
Of particular note is a B domain-truncated FVIII variant that includes 226 amino acids of native 
B domain and retains 6 potential consensus sites for N-linked glycosylation(226/N6).  This 
construct exhibited increased mRNA, improved ER-Golgi transport and reduced cellular (ER) 
stress[32-36].  As a single targeted modification, it exhibited up to 10-fold improved expression 
in preclinical experiments in vitro and in vivo
 
, including as part of viral vector-mediated gene 
transfer.  The challenge for the 226/N6 construct is that the overall size of the cDNA constrains 
efficient packaging within AAV vectors.  McIntosh and colleagues addressed this limitation by 
replacing the B domain sequence with a 17 amino acid peptide that contained 6 putative N-
linked glycosylation sites[37].  Following codon-optimization, this construct could be packaged 
more efficiently within rAAV vectors with a human liver-specific promoter as rAAV-HLP-codop-
hFVIII-V3 (or V3).   V3 was observed to be safe and efficacious within mice and non-human 
primates and is now being tested within human subjects in a phase I/II clinical trial for 
hemophilia A (NCT03001830, www.clinicaltrials.gov).  The investigators will test whether the 
higher efficacy observed with this construct in preclinical studies will allow satisfactory efficacy 
in humans at vector dosage levels that have already been observed to be safe in humans as part 
of AAV8 gene therapy for hemophilia B. 
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 Comparative biology is yielding some new insights for targeted bioengineering.  
Whereas human BDD-FVIII is secreted predominantly as a heterodimer, canine BDD-FVIII is 
secreted predominantly as a single chain polypeptide.  Canine BDD-FVIII has also been shown to 
be more stable and has a higher specific activity compared to the human form and that this 
could be attributed to suboptimal cleavage of the canine BDD-FVIII by furin[38].  Nguyen and 
colleagues hypothesized that deletion of part or all of the furin cleavage recognition sequence 
could increase the proportion of single chain human BDD-FVIII[39].  Two deletion variants were 
secreted primarily as single chain forms and had 2-fold higher procoagulant activity compared 
to BDD-FVIII when expressed from cell lines and achieved 2-4-fold higher expression in mouse 
plasma after AAV vector delivery.  In another example of comparative biology, Brown and 
colleagues used insights from characterization of porcine BDD-FVIII[40].  They generated a 
human-porcine hybrid designated ET3, consisting of human FVIII sequences within the FVIII A2, 
C1 and C2 domains and porcine sequences in the A1 domain and the activation peptide-A3 
domain.  The overall amino acid sequence substitution represented about 9% of the overall 
sequence but conferred between 10-100-fold improved biosynthesis in cell line expression 
systems.  When packaged into an AAV vector, AAV-ET3 achieved correction of FVIII in 
hemophilia A mice at lower vector doses than could be achieved with 100% human FVIII 
sequence constructs.  
Bioengineering through comparative biology 
 
 The bioengineering approaches described thus far are optimization of a protein through 
rational design.  An alternative approach to protein optimization is through ancestral sequence 
reconstruction (ASR).  This approach is based on the observation that extant FVIII orthologs 
have molecular, cellular and immune recognition properties that vary between species (eg. 
murine, canine, porcine, human).  The diversity is hypothesized to represent adaptive traits 
through pressures of natural selection to promote hemostatic balance.  The analysis of these 
differences can lead to insights toward leveraging bioengineered forms with enhanced 
functional properties.  Zakas and colleagues have gone beyond the work based on ortholog 
Ancestral comparative biology 
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scanning that led to the ET3 FVIII construct and have generated higher resolution mapping of 
FVIII protein sequences through comparisons of sequential phylogeny branches[41].  This led to 
the identification of ancestral FVIII constructs which demonstrated significantly higher FVIII 
production compared to human FVIII.  They hypothesize, based on observations with porcine 
FVIII and the ET3 FVIII constructs that the conferred increased secretion expression is mediated 
by reduced engagement of unfolded protein response pathways.  This ASR approach has also 
yielded insights on ancestral FVIII constructs with enhanced specific activity, stability and 
altered immune reactivity.  Insights from this analysis could lead to targeted modification of 
FVIII that may yield superior rFVIII versions or gene therapy constructs. 
 
Challenges to be addressed with bioengineered FVIII constructs 
    The clinical implementation of BDD-FVIII has not been without some challenges in 
clinical assays and potency assignment. BDD-FVIII activity may be up to 50% lower in one-stage 
aPTT assays compared to chromogenic assays[25, 42]. The mechanism for this discrepancy has 
yet to be fully explained.  There may be subtle conformational changes resulting from the B 
domain deletion that alter phospholipid interactions[43, 44].  The potency estimation of BDD-
FVIII is sensitive to factor X activation in the chromogenic assay with discrepancies noted 
between various chromogenic assay kits.  There may also be differences in the profile of FVIII 
activation by thrombin within each of the two types of assays that contributes to the 
discrepancy between BDD-FVIII and full-length FVIII.  This discrepancy can be abrogated by 
altering the composition of the source phospholipid such that phosphatidylserine content is 
maintained below 10%.  In 2003, due to these assay discrepancies and effects on potency 
assignment, a commercial BDD-FVIII (Xyntha/ReFacto AF, Pfizer, Boston, USA) was reformulated 
with 20% more drug product than the original formulation to achieve the stated potency[45].  
Calibration of the one-stage assay with a product-specific standard has also been 
recommended[25].  However, this has not eliminated some patient-specific factors that can 
contribute to discrepancy when assaying post-infusion plasma samples[46].   
One-stage/two-stage assay discrepancy 
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 Recombinant FVIII single chain (Afstyla, CSL Behring, Marburg, Germany) is a novel B-
domain truncated rFVIII in which the heavy and light chains of FVIII are covalently fused to 
achieve a single polypeptide protein[47, 48].  Following thrombin activation, it is structurally 
and functionally indistinguishable from endogenously generated FVIIIa.  However, it too 
demonstrates assay discrepancy measuring about 50% lower by one-stage assay compared to 
chromogenic assay (which is used for its potency assignment).    A laboratory field study 
demonstrated consistent and predictable differences in the assay results across laboratories 
and FVIII plasma concentrations allowing for a “correction factor” of 2 applied to the one stage 
assay results in order to align with chromogenic assay results[49]. 
 
 The ER, as the site of folding and disulfide bond formation for nascent secreted proteins, 
is a unique oxidating environment.  The unfolded protein response(UPR) is an adaptive 
signaling pathway that serves to prevent the accumulation of misfolded proteins within the ER 
and to minimize the stress of oxidative protein folding[35, 50].  Chronic unresolved 
accumulation of unfolded proteins within the ER leads to apoptosis.  FVIII has been shown to be 
prone to misfolding in the ER lumen, inducing ER stress-induced oxidative damage, activation of 
the UPR, and apoptosis.  This correlates with reduced FVIII expression in cellular expression 
systems in vitro as well as reduced plasma expression 
Unfolded protein response 
in vivo with gene transduction, including 
with viral gene therapy vectors.  Several bioengineered variants designed to alter ER chaperone 
interactions, and improve folding, have exhibited reduced UPR activation, oxidative stress and 
apoptosis and are associated with improved FVIII expression in vitro and in vivo
 Zolotukhin and colleagues used a codon optimized BDD-FVIII within an AAV vector to 
transduce wild-type C57BL/6 mice[52].  Though there was no resultant increase in ALT levels, 
.  A single 
missense mutation, F309S within a hydrophobic pocket of the FVIII A1 domain, enhances 
expression 2-fold[51] and further enhances the expression efficiency of the 226/N6 B domain 
variant up to 10-fold in a preclinical viral gene transfer study[32].  Given these observations, 
what evidence is there that FVIII constructs currently being evaluated for clinical gene therapy 
risk intracellular misfolding and resultant induction of UPR, oxidative stress and apoptosis? A
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there was upregulation of UPR sentinel chaperone proteins at increased doses of the AAV 
vector.  Notably, the same was not observed with null vectors or those containing a FIX 
transgene. Lange et al. also observed a delayed and transient cellular stress response in the 
liver in a hemophilia A mouse model when BDD-FVIII was delivered by AAV and was expressing 
at supraphysiological levels (>200%)[53].  Staber et al. showed that a lentiviral vector to deliver 
BDD-FVIII induced UPR and biochemical markers of ER stress that could be attenuated with a 
modified B domain that contains 11 engineered N-glycans[54].   Although, none of these studies 
demonstrated clear evidence of cellular toxicity, studies of FVIII expression in platelets have 
demonstrated that high expression of FVIII can lead to apoptosis[55]. 
 These animal model results suggest the potential for BDD-FVIII and its codon-optimized 
variants, to induce UPR and cellular stress within the ongoing clinical trial programs.  Previously 
noted BMN 270 was investigated within mice and cynomolgus monkeys[56].  BMN 270 
produced therapeutic levels of FVIII activity within an immune-incompetent double knockout 
mouse (FVIII and recombinant activating gene 2 knockouts).  Intracellular retention of FVIII was 
noted within hepatocytes.  However, they did not demonstrate any evidence for activation of 
the UPR when liver homogenates were evaluated 5, 12 and 24 weeks post-BMN-270 dosing.  
Given the observations in previous studies, these time points could have missed a transient UPR 
response.  Their study indicated that another construct with a stronger promoter did induce 
expression of molecular chaperones consistent with UPR activation. Although, detailed studies 
to evaluate for UPR activation were not performed in the monkeys, no elevation of plasma ALT 
or AST levels was observed. 
Within the Phase 1/2 BMN 270 study[57], 11 of the 15 subjects exhibited elevations in 
ALT (13 were Grade 1 and one was Grade 2) with 8 having accompanying increases in AST.  This 
included 6 of the 7 subjects at the highest AAV dose (6 x 10
13
 vg/kg) and 4 of the 6 subjects at 
the 4 x 10
13
 vg/kg dose. All of these were assessed as non-serious and of limited duration 
occurring between 0.4-15.4 weeks from the vector administration.  No subjects exhibited any 
evidence for a T cell-mediated immune response associated with the ALT elevations. The 
subjects in the BMN 270 trial, as has been typical in the other hemophilia programs, received a 
course of corticosteroids with the intent to blunt any immune response and salvage protein 
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expression.  However, if these ALT increases are a biomarker for, even transient, cellular stress 
from FVIII expression, corticosteroids may not be the optimal intervention.  This may provide an 
opportunity to explore the impact of bioengineered FVIII variants with improved folding and 
secretion efficiency and also consideration for the use of systemic anti-oxidants[35].       
 
 Although bioengineering has produced EHL-rFIX products with 3- to 5-fold half-life 
extension, EHL-rFVIII products have been limited to about 1.3- to 1.5-fold that of standard 
rFVIII[58].  This is likely due to their continued interaction with endogenous VWF where they 
are subject to clearance as part of the FVIII-VWF complex[59].  Novel bioengineering strategies 
are attempting to overcome this “ceiling” effect.  A VWF-albumin fusion protein exhibits a 
significant prolongation of VWF half-life 
Rapid clearance of FVIII from circulation 
in vivo[60]. However, as long as FVIII can distribute to 
unmodified endogenous VWF, this strategy would have a limited overall impact on FVIII half-
life.  However, it is now recognized that the D’D3 fragment of VWF, containing the FVIII-binding 
region, is sufficient to stabilize FVIII in vivo[61].  The D’D3 fragment can be modified to extend 
its half-life (targeted glycosylation, albumin/Fc fusion).  The challenge remains to increase the 
affinity of the D’D3-FVIII interaction to reduce redistribution to unmodified VWF in vivo
 
.  One 
strategy to address this is through a covalent linkage between a D’D3/Fc fusion and a rFVIIIFc 
fusion molecule[62].  The rFVIIIFc fusion molecule was further modified with unstructured 
hydrophilic, biodegradable polypeptide polymers (XTEN, Amunix, Mountain View, CA, USA).  
This covalent dimer of FVIII and D’D3 has demonstrated up to 4-fold longer half-life compared 
to unmodified rFVIII in a mouse model. 
 That few bioengineered FVIII molecules have been moved into clinical trials can be 
attributed in part to the significant immunogenicity of even the native molecule.  Strategies to 
reduce the immunogenicity of FVIII have been thus far elusive.  However, with new insights on 
how FVIII interacts with antigen-presenting cells, several approaches are being investigated.  
These include: the expression of rFVIII within human cell lines[63, 64] with the aim of retaining 
FVIII with reduced immunogenicity 
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human-specific post-translational modifications, such as its glycosylation profile; porcine-
human hybrids which eliminate highly immunogenic peptide sequences[65]; Fc-fusion and 
PEGylation[58]; targeted mutagenesis of the FVIII C1 and C2 domains[66] or fusion of FVIII with 
nanobodies with enhanced affinity for VWF[67], both of which aim to reduce dendritic cell 
endocytosis. 
 
Bioengineering of FIX 
The first wave of clinical trials for hemophilia B between 1996 and 2006 showed 
transient expression of FIX with correction of the bleeding phenotype[13].  AAV distinguished 
itself as having the best safety/efficacy and risk/benefit ratios and the liver was established as 
the most suitable target organ for expression.  However, the challenge of the host immune 
response including pre-existing immunity to AAV as well as a cytotoxic immune response to the 
vector capsid limited the success of these early trials.  This led to investment in additional 
preclinical studies to improve the vectors through investigation of alternative serotypes with 
improved transduction efficiency, improvements in the transgene and promoters and better 
understanding of the mechanisms of the immune response.  The proof of concept for gene 
therapy for hemophilia B was achieved between 2010 and 2014.  Despite low plasma levels of 
FIX (~2-5%), the expression has been durable and has been accompanied by correction of the 
bleeding phenotype (>90% bleed reduction and liberation from the need for regular FIX 
prophylaxis)[68].  Nevertheless, the continued problem of a cytotoxic response has precluded 
simply delivering higher doses of vector to target higher plasma levels of FIX. 
FIX Padua 
The current wave of clinical trials for gene therapy are all benefitting from use of a 
bioengineered FIX construct with higher specific activity.   Although these trials have applied 
some additional improvements in vector design and immunomodulation, the most impactful 
innovation has been the use of a point mutation (R338L) in FIX.  This is a naturally-occurring FIX 
mutation described originally by Simioni et al. at the University of Padua, identified within a 
family with inherited thrombophilia who expressed this form of FIX[69].  These patients 
demonstrated up to an 8-fold higher plasma activity of FIX, all attributable to a higher specific 
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activity conferred by this point mutation.  FIX Padua had been investigated in a number of 
preclinical studies and exhibited a 5-10-fold increase in activity in every context regardless of 
the vector used or target cell.  FIX Padua has now been used in two clinical trials[70, 71] thus far 
and is to be incorporated into a third. In the study reported by George and colleagues[70], FIX 
Padua as part of an AAV-based gene therapy targeting the liver achieved sustained FIX plasma 
activity of 33.7 + 18.5% (range 14-81%) across 9 subjects at a vector dose of 5 x 10
11
 
 vg/kg.  Not 
only did this level or expression obviate the need for FIX infusions but it virtually eliminated all 
spontaneous bleeding events.  This represents an important pairing of improvements in gene 
therapy vector design with the advantages of a bioengineered construct. 
 Not all bioengineering strategies with FIX are being applied only to gene therapy 
constructs.  You et al. have described a bioengineered rFIX with enhanced biological properties 
that allows for alternative delivery strategies[72].  Through a rational design approach they 
have bioengineered rFIX with resistance to inhibition by antithrombin, increased affinity for 
FVIIIa and increased catalytic activity.  This modified rFIX, CB2679d/ISU304, exhibits 22-fold 
enhanced potency in an in vitro clotting assay and in vivo via a murine tail clip model and has an 
8-fold enhanced duration of aPTT activity in vivo compared with wild-type rFIX.  These 
enhanced properties are being evaluated in a clinical trial (NCT03186677, 
www.clinicaltrials.gov) administered subcutaneously for prophylaxis.  The pharmacokinetic 
profile was evaluated in several cohorts in a crossover, ascending dose design compared to IV 
standard recombinant FIX confirming the 22-fold greater potency and long mean residence 
time.  This is now being evaluated in a final cohort with daily subcutaneous dosing.  Modeling 
from the preclinical studies suggests that subjects should be able to maintain normal plasma 
levels of FIX with a daily subcutaneous administration.  
Bioengineered FIX for subcutaneous delivery 
 
Conclusions 
 The current wave of recombinant therapeutics for hemophilia have seen the benefits of 
bioengineering, leading to EHL factor products, enhanced specific activity to improve the 
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efficacy and safety of gene therapy and introduced the first non-factor therapeutic, a bispecific 
antibody.  Even the current novel products will likely be supplanted through additional 
bioengineering efforts to further enhance pharmacokinetic profiles, reduce the immunogenicity 
of factor VIII, and even improve on the efficacy of bispecific antibodies as a factor VIIIa-mimetic.  
The next wave of therapeutics may be influenced from new insights from analyses of next-
generation sequencing and transcriptome databases that hope to elucidate new targets for 
bioengineering.    
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Table 1. Bioengineering strategies for enhanced biologics 
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Table 2. Bioengineering Factor VIII for improved expression
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